𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Early prostate cancer – which treatment do men prefer and why?

✍ Scribed by Carmel N. Anandadas; Noel W. Clarke; Susan E. Davidson; Patrick H. O’Reilly; John P. Logue; Lynne Gilmore; Ric Swindell; Richard J. Brough; Guy D. Wemyss-Holden; Maurice W. Lau; Pradip M. Javle; Vijay A.C. Ramani; James P. Wylie; Gerald N. Collins; Stephen Brown; Richard A. Cowan; On behalf of the North West Uro-oncology Group

Book ID
110923323
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
546 KB
Volume
107
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Common mutations in BRCA1 and BRCA2 do n
Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men
✍ Nastiuk, Kent L.; Mansukhani, Mahesh; Terry, Mary Beth; Kularatne, Piyumika; Rub 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 262 KB 👁 1 views

BACKGROUND. Families with a high incidence of hereditary breast cancer, and subsequently shown to have terminating mutations in BRCA1 or BRCA2, appear to have a higher incidence of prostate cancer among male relatives. We aimed to determine whether the common germline mutations of BRCA1 or BRCA2 in

Treatment ‘mismatch’ in early prostate c
Treatment ‘mismatch’ in early prostate cancer : Do treatment choices take patient quality of life into account?
✍ Ronald C. Chen; Jack A. Clark; Judith Manola; James A. Talcott 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## BACKGROUND. Pretreatment urinary, bowel, and sexual dysfunction may increase the toxicity of prostate cancer treatments or preclude potential benefits. Using patient‐reported baseline dysfunction from a prospective cohort study, we determined the proportion of patients receiving rel